Palisade Bio, Inc. announced on October 1, 2025, the pricing of an upsized underwritten public offering of 171,440,559 shares of its common stock (or common stock equivalents) at a public offering price of $0.70 per share. This offering is expected to generate gross proceeds of approximately $120 million.
The company has also granted the underwriters a 45-day option to purchase up to an additional 25,714,285 shares of common stock at the public offering price. The offering is anticipated to close on or about October 2, 2025, subject to customary closing conditions.
This significant capital raise is intended to fund the company's operations and advance its clinical programs. However, the offering price of $0.70 per share indicates substantial dilution for existing shareholders, reflecting the company's need for financing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.